S Han1, M Wang2, B Liu1, J Yu3. 1. The Department of Oncology, Shandong Cancer Hospital and Institute, Shandong University, No. 440 of Jiyan Road, Jinan, 250117, Shandong, People's Republic of China. 2. The Department of Oncology, Jiaozhou Central Hospital of Qingdao, No. 29 of Xuzhou Road, Jiaozhou, Qingdao, 266300, Shandong, People's Republic of China. 3. The Department of Oncology, Shandong Cancer Hospital and Institute, Shandong University, No. 440 of Jiyan Road, Jinan, 250117, Shandong, People's Republic of China. Yujinming2015@126.com.
Abstract
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of a consecutive series of elderly patients with primary central nervous system lymphoma (PCNSL) treated with single-agent pemetrexed without radiotherapy or intrathecal chemotherapy. METHODS: Twelve histologically confirmed newly diagnosed PCNSL patients older than 65 years were studied between 2008 and 2013. An induction chemotherapy was initially given (pemetrexed 600 mg/m(2) on day 1, every 3 weeks). Patients achieving a complete, partial response or stable disease proceeded to a maintenance phase (up to 6 cycles). Patients with progressive/recurrent disease (PD) were treated with whole brain radiotherapy on an individual basis. RESULTS: Four patients presented complete response, six patients showed partial response and two patients presented progressive disease. The median progression-free survival (PFS) was 9.0 months [95 % confidence interval (CI) 2.0-45.3] and the median overall survival was 19.5 months (95 % CI 5.0-45.3). Adverse events included leukocytopenia, anemia, fatigue, rash and vomiting. No neurotoxicity or treatment-related death was observed. The estimated 1-year and 2-year survival rate was 66.7 and 41.7 %, respectively. CONCLUSIONS: Our efficacy results demonstrate that the single-agent pemetrexed was feasible, active and well tolerated in elderly patients with PCNSL. Furthermore, this single-agent regimen results in higher response rates and less toxicity comparable with other chemotherapy or radiotherapy regimens. Prospectively, controlled studies are warranted to confirm such results.
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of a consecutive series of elderly patients with primary central nervous system lymphoma (PCNSL) treated with single-agent pemetrexed without radiotherapy or intrathecal chemotherapy. METHODS: Twelve histologically confirmed newly diagnosed PCNSLpatients older than 65 years were studied between 2008 and 2013. An induction chemotherapy was initially given (pemetrexed 600 mg/m(2) on day 1, every 3 weeks). Patients achieving a complete, partial response or stable disease proceeded to a maintenance phase (up to 6 cycles). Patients with progressive/recurrent disease (PD) were treated with whole brain radiotherapy on an individual basis. RESULTS: Four patients presented complete response, six patients showed partial response and two patients presented progressive disease. The median progression-free survival (PFS) was 9.0 months [95 % confidence interval (CI) 2.0-45.3] and the median overall survival was 19.5 months (95 % CI 5.0-45.3). Adverse events included leukocytopenia, anemia, fatigue, rash and vomiting. No neurotoxicity or treatment-related death was observed. The estimated 1-year and 2-year survival rate was 66.7 and 41.7 %, respectively. CONCLUSIONS: Our efficacy results demonstrate that the single-agent pemetrexed was feasible, active and well tolerated in elderly patients with PCNSL. Furthermore, this single-agent regimen results in higher response rates and less toxicity comparable with other chemotherapy or radiotherapy regimens. Prospectively, controlled studies are warranted to confirm such results.
Entities:
Keywords:
Chemotherapy; Elderly; Pemetrexed; Primary central nervous system lymphoma
Authors: Benjamin Kasenda; Marcel Rehberg; Petra Thürmann; Melanie Franzem; Hendrik Veelken; Kristina Fritsch; Elisabeth Schorb; Jürgen Finke; Dirk Lebiedz; Gerald Illerhaus Journal: Ann Hematol Date: 2012-03-29 Impact factor: 3.673
Authors: D F Nelson; K L Martz; H Bonner; J S Nelson; J Newall; H D Kerman; J W Thomson; K J Murray Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: Douglas E Ney; Anne S Reiner; Katherine S Panageas; Hayley S Brown; Lisa M DeAngelis; Lauren E Abrey Journal: Cancer Date: 2010-10-01 Impact factor: 6.860
Authors: Antonio M P Omuro; Leah S Ben-Porat; Katherine S Panageas; Amy K Kim; Denise D Correa; Joachim Yahalom; Lisa M Deangelis; Lauren E Abrey Journal: Arch Neurol Date: 2005-10
Authors: Patrick Roth; Peter Martus; Philipp Kiewe; Robert Möhle; Hermann Klasen; Michael Rauch; Alexander Röth; Stephan Kaun; Eckhard Thiel; Agnieszka Korfel; Michael Weller Journal: Neurology Date: 2012-08-15 Impact factor: 9.910
Authors: Jeffrey J Raizer; Alfred Rademaker; Andrew M Evens; Laurie Rice; Margaret Schwartz; James P Chandler; Christopher C Getch; Claudia Tellez; Sean A Grimm Journal: Cancer Date: 2011-12-16 Impact factor: 6.860
Authors: G Illerhaus; R Marks; F Müller; G Ihorst; F Feuerhake; M Deckert; C Ostertag; J Finke Journal: Ann Oncol Date: 2008-10-26 Impact factor: 32.976
Authors: Delia Kurzwelly; Martin Glas; Patrick Roth; Elke Weimann; Hanns Lohner; Andreas Waha; Martin Schabet; Guido Reifenberger; Michael Weller; Ulrich Herrlinger Journal: J Neurooncol Date: 2009-10-20 Impact factor: 4.130
Authors: Jorg Dietrich; Laura Versmee; Jan Drappatz; April F Eichler; Lakshmi Nayak; Andrew Norden; Eric Wong; Michelle R Pisapia; SooAe S Jones; Amanda B Gordon; Bruce A Chabner; Fred Hochberg; Tracy T Batchelor Journal: Oncologist Date: 2020-07-01
Authors: Ioannis Siasios; Aggeliki Fotiadou; George Fotakopoulos; Maria Ioannou; Vassilios Anagnostopoulos; Konstantinos Fountas Journal: J Clin Med Res Date: 2015-10-23